Evidence map›Paper›PMID 37382259›Full record

ArticleImmunity, inflammation and disease2023

Cord blood antibodies following BBIBP-CorV (Sinopharm) vaccination during pregnancy.

Sedigheh Hantoushzadeh, Nasim Eshraghi, Sarang Younesi, Mohammadreza Salehi, Nima Rezaei, Mohammad Mehdi Hasheminejad, Pegah Rashidian, Saeedeh Shirdel, Fatemeh Asadi, Marjan Ghaemi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, inflammation and disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Sedigheh HantoushzadehVali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Nasim EshraghiVali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Sarang YounesiNilou Laboratory, Prenatal Screening Department, Tehran, Iran.
Mohammadreza SalehiDepartment of Infectious Diseases, Tehran University of Medical Sciences, Tehran, Iran.
Nima RezaeiDepartment of Immunology, Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Mehdi HasheminejadVali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Pegah RashidianVali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Saeedeh ShirdelVali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh AsadiVali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
Marjan GhaemiVali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0003-2306-7112
Tehran University of Medical Sciences · IRChildren's Medical Center · IRNational Iranian Oil Company (Iran) · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to evaluate the maternal and umbilical cord blood antibody levels, after COVID vaccination during pregnancy.

methodThe women who received the COVID-19 vaccine (Sinopharm) during pregnancy were included. Maternal and cord blood samples were tested to detect the severe acute respiratory syndrome coronavirus 2 receptor binding domain (RBD) specific antibodies. In addition, obstetric information and side effects after vaccination were gathered.

resultA total of 23 women were included. Eleven pregnant women took two doses and 12 cases received a single dose of the vaccine. No IgM antibody was detected in any maternal blood or cord blood samples. The RBD-specific Immunoglobulin G (IgG) antibody was positive in mothers receiving 2 doses of the vaccine and their infants. But the antibody titers were under the positive cut-off threshold for the other 12 women who were vaccinated with a single dose. Women who received both doses of vaccine had significantly higher IgG levels than a single dose of Sinopharm (p = .025). The same result was demonstrated in infants born to these mothers (p = .019).

conclusionThere was a significant correlation between maternal and neonatal IgG concentrations. Although, receiving both doses of the BBIBP-CorV vaccine (not 1 dose) during pregnancy is highly beneficial for increasing humoral immunity for the mother and fetus.

Indexed as

COVID-19COVID-19 VaccinesPregnancy Complications, InfectiousAntibodies, ViralFemaleFetal BloodHumansImmunoglobulin GInfantInfant, NewbornPregnancyVaccinationVaccines, InactivatedAntibodies, ViralBIBP COVID-19 vaccineCOVID-19 VaccinesImmunoglobulin GVaccines, Inactivatedantibodycord bloodCOVID-19Iranmaternal mortalitypregnancySinopharmvaccine

Identifiers

PMID37382259
PMCPMC10266141
OpenAlexW4380683239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.